Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

4.0%

1 terminated/withdrawn out of 25 trials

Success Rate

90.9%

+4.4% vs industry average

Late-Stage Pipeline

80%

20 trials in Phase 3/4

Results Transparency

0%

0 of 10 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 4
18(78.3%)
Phase 3
2(8.7%)
Phase 1
2(8.7%)
N/A
1(4.3%)
23Total
Phase 4(18)
Phase 3(2)
Phase 1(2)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (25)

Showing 20 of 25 trials
NCT07281677Phase 4Recruiting

Immunogenicity and Safety of Sequential 2vHPV-9vHPV Vaccination in Girls Aged 9-14 Years

Role: lead

NCT07133802Phase 3Not Yet Recruiting

Clinical Trial to Evaluate the Protective Efficacy and Safety of a Nasal Spray Live Attenuated Influenza Vaccine (LAIV) in Adults Aged 18-59 Years Post-Vaccination

Role: collaborator

NCT05930717Withdrawn

Zhejiang Nutrition and Health Study

Role: collaborator

NCT06825312Phase 4Active Not Recruiting

Immunogenicity, Safety, and Antibody Persistence of Different Immunization Strategies Against Japanese Encephalitis

Role: collaborator

NCT05205096Phase 1Completed

Immunogenicity and Safety of Booster Immunization of ZF2001 After Inoculation With Two Doses of CoronaVac

Role: collaborator

NCT05870618Phase 4Unknown

Immunogenicity and Safety of DTaP or DT Vaccine in 6 Year Old Children

Role: lead

NCT05870631Phase 4Unknown

Immunogenicity and Safety of DTaP or DT Vaccine in 6 Year Old Children ( DTaP/DT )

Role: lead

NCT04817917Phase 4Unknown

Seroprevalence of Neutralizing Antibodies Against Japanese Encephalitis Virus Among 6 Years Old Children With 5 Different Immunization Strategies in Zhejiang Province

Role: lead

NCT04091880Phase 4Completed

Evaluation of the Safety and Immunogenicity of Simultaneously Administration of EV71 Vaccine and Influenza Vaccine

Role: collaborator

NCT04133584Phase 4Completed

The Immunogenicity and Safety of the Vaccination of Inactivated Enterovirus 71 Vaccine and Seasonal Influenza Vaccine

Role: lead

NCT05415345Phase 4Unknown

Immunogenicity and Safety of Co-immunization With Cecolin and Hecolin

Role: collaborator

NCT05373030Phase 4Unknown

Sequential Immunization With Recombinant Adenovirus Type-5-vectored COVID-19 Vaccine in Health Adults Based on 3 Doses Inactivated COVID-19 Vaccine

Role: lead

NCT05279248Phase 4Unknown

The Immunogenicity and Safety of the Vaccination of Human Papillomavirus Vaccine and Measles-Mumps-Rubella Vaccine

Role: lead

NCT04576910Phase 4Completed

Immunogenicity and Safety of the Booster Dose of Polio Vaccine With Different Primary Sequential Schedules in China

Role: lead

NCT05205083Phase 1Unknown

Immunogenicity and Safety of Booster Immunization of ZF2001 After Inoculation With Two Doses of BBIBP-CorV

Role: collaborator

NCT05105295Phase 4Unknown

Immunogenicity and Safety of a Third Dose and Immune Persistence of BBIBP-Corv Vaccine in People With HIV Infected

Role: collaborator

NCT05104216Phase 4Unknown

Immunogenicity and Safety of a Third Dose and Immune Persistence of BBIBP-Corv Vaccine in Elderly People With Chronic Bronchitis and COPD

Role: collaborator

NCT05075083Phase 4Unknown

Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in Elderly People With Chronic Bronchitis and COPD

Role: collaborator

NCT05075070Phase 4Unknown

Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in People With HIV Infected

Role: collaborator

NCT03147560Phase 4Completed

Immunogenicity and Safety Evaluation of Different Sequential Immunization Strategies by Sabin IPV and bOPV in Chinese Infants

Role: lead